First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 12, 2026. The filing discloses that the Company has issued a press release announcing positive topline data from the first Phase 1b cohort of its investigational drug candidate ANB033 in the treatment of Celiac Disease.
The filing also indicates that the Company has updated its corporate investor presentation, which is attached to the report as Exhibit 99.1. The registrant is based in San Diego, California, and trades on the Nasdaq Stock Market LLC under the ticker symbol TRAX.
